Coagulation Factor Xa Has No Effects on the Expression of PAR1, PAR2, and PAR4 and No Proinflammatory Effects on HL-1 Cells.
Lukas RufAlicja BukowskaAndreas GardemannAndreas GoettePublished in: Cells (2023)
Atrial fibrillation (AF), characterised by irregular high-frequency contractions of the atria of the heart, is of increasing clinical importance. The reasons are the increasing prevalence and thromboembolic complications caused by AF. So-called atrial remodelling is characterised, among other things, by atrial dilatation and fibrotic remodelling. As a result, AF is self-sustaining and forms a procoagulant state. But hypercoagulation not only appears to be the consequence of AF. Coagulation factors can exert influence on cells via protease-activated receptors (PAR) and thereby the procoagulation state could contribute to the development and maintenance of AF. In this work, the influence of FXa on Heart Like-1 (HL-1) cells, which are murine adult atrial cardiomyocytes (immortalized), was investigated. PAR1, PAR2, and PAR4 expression was detected. After incubations with FXa (5-50 nM; 4-24 h) or PAR1- and PAR2-agonists (20 µM; 4-24 h), no changes occurred in PAR expression or in the inflammatory signalling cascade. There were no time- or concentration-dependent changes in the phosphorylation of the MAP kinases ERK1/2 or the p65 subunit of NF-κB. In addition, there was no change in the mRNA expression of the cell adhesion molecules (ICAM-1, VCAM-1, fibronectin). Thus, FXa has no direct PAR-dependent effects on HL-1 cells. Future studies should investigate the influence of FXa on human cardiomyocytes or on other cardiac cell types like fibroblasts.
Keyphrases
- atrial fibrillation
- induced apoptosis
- left atrial
- catheter ablation
- cell cycle arrest
- high frequency
- poor prognosis
- signaling pathway
- oral anticoagulants
- left atrial appendage
- heart failure
- direct oral anticoagulants
- oxidative stress
- stem cells
- cell adhesion
- cell proliferation
- endoplasmic reticulum stress
- percutaneous coronary intervention
- photodynamic therapy
- risk factors
- binding protein
- immune response
- venous thromboembolism
- coronary artery disease
- systemic sclerosis
- single molecule
- extracellular matrix
- acute coronary syndrome
- cell therapy
- lps induced
- mitral valve